ClinicalTrials.Veeva

Menu

Immuno 1: Immune Reconstitution Following Conventional or High-Dose Chemotherapy With Stem Cell Transplant

J

Julius-Maximilians University

Status

Unknown

Conditions

Medulloblastoma
Leukemia

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

The purpose of this study is to conduct an analysis of the influences of

  1. conventional chemotherapy
  2. high-dose chemotherapy followed by autologous stem cell transplant
  3. high-dose chemotherapy followed by allogeneic stem cell transplant on the recovery of the immune system.

Detailed analysis will help to better understand the pathways of recovery of the immune system following chemotherapy as well as the pathways of recovery of the immune system following autologous or allogeneic stem cell transplantation.

Full description

Detailed analysis will be performed at preselected time points following therapy by

  • standard flow cytometry in combination with intracellular cytokine/antigen staining
  • spectratype analysis
  • TREC assays

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Acute leukemia treated according to current ALL-BFM 2002 protocol
  • Solid tumor treated according to current GPOH-protocol
  • Medulloblastoma treated according to HIT-2000 protocol
  • High-dose chemotherapy followed by autologous stem cell transplantation
  • High-dose chemotherapy followed by allogeneic stem cell transplantation
  • Written consent according to our institutional guidelines

Exclusion criteria

  • No written consent

Trial contacts and locations

1

Loading...

Central trial contact

Beate Winkler, MD; Paul G Schlegel, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems